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ABSTRACT
The Economic Value of Pharmacist-Physician Collaborative Care Models in
Hypertension Management
By Jessica S. Jay, PharmD
A Thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
in Pharmaceutical Sciences with a concentration in pharmacoeconomics and health outcomes at
Virginia Commonwealth University
Virginia Commonwealth University, 2022
Advisor: Julie A. Patterson, PharmD, PhD
Assistant Professor, Department of Pharmacotherapy and Outcomes Science
Background: Hypertension is highly prevalent in the United States, affecting nearly half of all
adults (43%). Studies have shown that pharmacy-physician collaborative care models (PPCCM)
for hypertension management significantly improve blood pressure (BP) control rates and provide
consistent control of BP. Time in target range (TTR) for systolic BP is a novel measure of BP
control consistency that is independently associated with decreased cardiovascular (CV) risk.
There is no evidence observed improvement in TTR for systolic BP with PPCCM is cost effective.
Objective: This study aimed to compare the cost-effectiveness of PPCCM with usual care for the
management of hypertension from the payer perspective with a decision analysis model and a
Markov model.
Methods: Both the decision analysis model and the Markov model utilized a three-year time
horizon based on published literature and publicly available data. The population consisted of adult
patients who had a previous diagnosis of high BP (defined as office-based BP  140/90 mmHg) or
were receiving antihypertensive medication(s). Effectiveness data were drawn from two published
studies evaluating the effect of PPCCM (vs. usual care) on TTR for systolic BP and the impact of
TTR for systolic BP on four CV outcomes (nonfatal myocardial infarction (MI), stroke, heart
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failure (HF), and cardiovascular disease (CVD) death). Both models incorporated direct medical
costs, including both programmatic costs (i.e., direct costs for provider time) and downstream
healthcare utilization associated with the acute CV events; the Markov model also included the
incremental post-CV event costs and recurrences of the same acute CV event. One-way sensitivity
and threshold analyses examined model robustness.
Results: In base case analyses for the decision analysis model and Markov model, PPCCM
hypertension management was associated with lower downstream medical expenditures
(difference: -$162.86 and -$173.05, respectively) and lower total program costs (difference: $108.00) per person treated when compared to usual care. PPCCM was associated with lower
downstream medical expenditures across all parameter ranges tested in the deterministic sensitivity
analysis. For every 10,000 hypertension patients managed with PPCCM vs. usual care over a threeyear time horizon, the decision analysis and Markov models suggested that approximately 27 and
16 CVD deaths, 29 and 51 strokes, 21 and 42 non-fatal MIs, and 12 and 48 incident HF diagnoses,
respectively, are expected to be averted.
Conclusion: This is the first study to model the cost-effectiveness of PPCCM compared to usual
care on TTR for systolic BP in adults with hypertension. For both the decision analysis and Markov
models, PPCCM was less costly to administer and resulted in downstream healthcare savings and
fewer acute CV events relative to usual care. Although further research is needed to evaluate the
long-term costs and outcomes of PPCCM, payer coverage of PPCCM services may prevent future
healthcare costs and improve patient CV outcomes.
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CHAPTER 1: INTRODUCTION
Section 1.1: Background
Hypertension is highly prevalent in the United States (US), affecting nearly half of all
adults (47%).1 Hypertension is defined as having a systolic blood pressure (BP) ≥ 130 or diastolic
BP ≥ 80 mmHg and is a major risk factor for ischemic heart disease, heart failure (HF), stroke,
chronic kidney disease, and death.1,2 Only about a quarter (24%) of adults with hypertension have
it under control. From 2003-2014, it was estimated that hypertension accounts for $131 billion per
year in US healthcare costs.3
It has been shown that high BP variability is associated with increased risks of all-cause
mortality, coronary heart disease, stroke, and end-stage renal disease.4–6 The concept of time in
target range (TTR) for systolic BP is a novel measure of BP variability.7 A longitudinal study from
15 Veterans Administration Medical Centers categorized TTR for systolic BP into 4 quartiles (025%, 26-50%, 51-75%, and 76-100%) and found an inverse and gradual association between time
in therapeutic range and all-cause mortality.7 To determine if TTR for systolic BP had an effect on
cardiovascular (CV) outcomes, Fatani et al. conducted a post hoc analysis of the SPRINT data.8,9
In the fully adjusted models, the authors found that for every one standard deviation increase in
TTR for systolic BP, the risk of first major adverse cardiovascular event (MACE) was significantly
decreased.8 This study is consistent with other studies suggesting greater variability in BP is
associated with coronary heart disease, stroke, CV mortality, and all-cause mortality.4–6
Studies have shown that pharmacists play a key role within primary care settings in
managing chronic diseases, such as hypertension, and clinical pharmacy services decrease overall
healthcare costs.10–12 A pharmacy-physician collaborative care model (PPCCM) is a practice
model where pharmacists provide medication management for common primary care conditions
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often under a collaborative practice agreement (CPA) with a physician to adjust medications, as
well as order necessary laboratory tests to monitor drug therapy. 13 Pharmacy-physician
collaborative care model has been shown to not only be successful within an office-based setting,13
but even within barbershops and churches.14,15 A study by Matzke et al. found significant
improvements (p < 0.01) in hemoglobin, BP, and cholesterol in patients with multiple chronic
conditions that were in the PPCCM group compared to those seen by usual care. Additionally,
hospitalizations declined within the PPCCM group, which led to an estimated cost savings of
$2,619 per patient.16 Carter et al. have conducted multiple randomized clinical trials to assess the
effectiveness of PPCCM for hypertension management and found that patients treated under the
PPCCM model achieve significantly better mean BP and overall BP control rates. 17,18 Recently, a
study conducted by Dixon et al. investigated the impact of PPCCM on TTR for systolic BP, as
defined by the proportion of clinical encounters with systolic BP between 120-140 mmHg during
a 12-month follow-up period.13 The mean TTR for systolic BP was significantly higher among
PPCCM patients (46.2% ± 24.3%) than patients who received usual care (24.8% ± 27.4%) (p <
0.0001).13 Additionally, a majority of patients in the usual care group had a TTR for systolic BP
in the lowest quartile (0-25%), while PPCCM patients were more likely to have TTR for systolic
BP in the highest quartile (76-100%).13
Section 1.2: Objective and Specific Aims
Despite the available evidence supporting PPCCM as an effective model at improving TTR
for systolic BP compared to usual care13 and that patients with higher TTR for systolic BP have
decreased risk of adverse CV events,

7–9

no pharmacoeconomic analysis has combined these

findings to model the cost-effectiveness of PPCCM. Therefore, the objective of this study was to
compare the cost-effectiveness of PPCCM with usual care on TTR for systolic BP in patients with
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hypertension utilizing two commonly utilized modeling approaches: a BP-based decision analysis
model and a BP-based Markov model. This study was conducted from the payer perspective to
quantify the value added to a payer of covering PPCCM services.
Specific Aim 1:
To assess the cost-benefit and cost-effectiveness of PPCCM relative to usual care in patients with
hypertension with a TTR for systolic BP-based decision analysis model.
Specific Aim 2:
2a. To assess the cost-benefit and cost-effectiveness of PPCCM relative to usual care in patients
with hypertension with a TTR for systolic BP-based Markov model.
2b. To compare the cost-benefit and cost-effectiveness of PPCCM relative to usual care in patients
with hypertension as assessed by the decision analysis and Markov models.
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CHAPTER 2: LITERATURE REVIEW
Section 2.1: Hypertension
Hypertension occurs when the force exerted by circulating blood against the walls of the
body’s arteries is too high.19 It is a serious medical condition that increases the risk ischemic heart
disease, HF, stroke, chronic kidney disease, and death.1,2 The US Centers for Disease Control and
Prevention reports that approximately 116 million Americans – nearly one out of two adults - have
hypertension. Further, over half a million Americans die annually from high BP or an event for
which high BP contributed.1
Blood pressure consists of two numbers, systolic and diastolic BP. The systolic number
represents the pressure in blood vessels when the heart contracts or beats, and the diastolic number
represents the pressure in the vessels when the heart rests between beats.19 Hypertension is
diagnosed if the patient’s systolic BP reading is 140 mmHg and/or their diastolic BP reading is
90 mmHg on two separate days (Table 1).1,19 Both modifiable and non-modifiable risk factors
contribute to hypertension. Modifiable risk factors include physical inactivity, consumption of
tobacco and alcohol, and being overweight. Diets high in salt, saturated fat, trans fat, and low in
fruits and vegetables also contribute to hypertension risk.2,19 Non-modifiable risk factors include
coexisting diseases, family history of hypertension, and age over 65 years. 2,19 Although
hypertension is known as the “silent killer”, some patients experience symptoms such as early
morning headaches, nosebleeds, irregular heart rhythms, vision changes, and buzzing in the ears.
Patients with severe hypertension can have symptoms that include fatigue, nausea, vomiting,
confusion, anxiety, chest pain, and muscle tremors.19
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Table 1: Blood Pressure Categories
Blood Pressure Category

Systolic mmHg
(upper number)

Diastolic mmHg
(lower number)

Normal

Less than 120

And

Less than 80

Elevated

120 – 129

And

Less than 80

High Blood Pressure
(Hypertension) Stage 1

130 – 139

Or

80 – 89

High Blood Pressure
(Hypertension) Stage 2

140 or higher

Or

90 or higher

Hypertensive Crisis
(consult doctor immediately)

Higher than 180

And / Or

Higher than 120

Blood pressure control, through lifestyle modifications with or without medications, is
critically important to the treatment of hypertension and the reduction of its humanistic and
economic burden.20 In the US, controlled BP is defined as systolic BP <130 mmHg and diastolic
BP <80 mmHg.21,22 Uncontrolled BP, even among patients treated with antihypertensives, is
associated with higher risk of all-cause, cardiovascular disease (CVD)-specific, heart-disease
specific, and cerebrovascular disease-specific mortality. Conversely, hypertension patients whose
BP is adequately controlled are not at increased risk of mortality later in life compared to patients
who are either untreated for their hypertension or have uncontrolled hypertension. 20 Despite the
well-documented consequences of uncontrolled hypertension, fewer than 1 in 4 Americans (24%)
with hypertension have it under control.1
Section 2.2: Time in Target Range for Systolic Blood Pressure
As previously discussed, despite clear evidence of the positive health outcomes associated
with hypertension control, control rates have remained suboptimal and even worsened over the
years.21 Blood pressure control has historically been defined by BP(s) taken at a single clinical
visit, with the last recorded BP of a calendar year determining BP control for performance
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measurement purposes.8 However, BP is a dynamic measure that fluctuates over time. Even
without any change in a patient’s drug regimen, BP can vary throughout the day and over time,
including from physician visit to physician visit.7 Therefore, the last recorded BP measurement
may not adequately reflect hypertension control. Studies have shown that high BP variability is
associated with increased risks of all-cause mortality, coronary heart disease, stroke, and end-stage
renal disease.4–6 Therefore, appropriate performance measure and clinical management of systolic
BP should account for the variation both within and out of target range. By expressing the
percentage of BP measurements in a patient’s therapeutic range (e.g., TTR for systolic BP range
120-140mmHg), TTR incorporates both the patient’s average BP value prevailing during longterm follow up and their degree of BP variability.7 This concept of TTR for systolic BP is a novel
measure of BP variability and control7 and has the potential to become a favored performance
measure for hypertension.
The following studies are a summarization of literature that discuss how variability of BP
is associated with myocardial structure, MACE, CVD, and all-cause mortality. These studies were
selected for additional discussion based on their inclusion of systolic BP variability and its
cardiovascular health consequences. A cohort study by Nwabuo et al. utilized data from the
Coronary Artery risk Development in Young Adults (CARDIA) study to evaluate associations
between visit-to-visit BP variability in early adulthood and myocardial structure and function in
middle age.23 Patients within the CARDIA study were aged 18 to 30 years at baseline and were
followed for 30 years, including 8 visits over 25 years and an echocardiogram at year 5. The study
results suggested that every 1-standard deviation increase in visit-to-visit systolic BP variability
was associated with higher left-ventricular mass (p < 0.001), worse diastolic function (p < 0.001),
higher left-ventricular filling pressures (p < 0.001), and worse global longitudinal strain (p =
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0.002). Additionally, greater visit-to-visit diastolic BP variability was associated with higher leftventricular mass (p < 0.001), worse diastolic function (p < 0.001), and worse global longitudinal
strain (p = 0.02). They concluded that greater visit-to-visit systolic and diastolic BP variability was
associated with adverse alterations in cardiac structure that were independent of mean BP levels. 23
A systematic review and meta-analysis by Wang et al. examined the association between
visit-to-visit variability of BP, CVD and all-cause mortality. This study searched PubMed and
EMBASE up until May 18, 2014 with the following terms: visit-to-visit variability, blood pressure,
cardiovascular disease, coronary heart disease, myocardial ischemia, stroke, and mortality. In their
primary analyses of 23 included studies (Table 2), Wang et al. found that increased BP variability
was significantly associated with outcomes of all-cause mortality (RR = 1.14; 95% CI: 1.05, 1.09),
CVD mortality (RR = 1.18; 95% CI: 1.09, 1.28), coronary heart disease (RR = 1.12; 95% CI: 1.06,
1.19), and stroke incidence (RR = 1.34; 95% CI: 1.11, 1.61). This meta-analysis incorporated
studies in heterogenic and high-risk populations, suggesting that standardized approaches of
monitoring visit-to-visit variability of BP are necessary for diverse patients.5
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Table 2: Baseline Characteristics of Studies Included in Wang et al. Meta-Analysis on the
Association Between Visit-to-Visit Variability of BP, CVD and All-Cause Mortality5

Abbreviations Used: ASCOT-BPLA, Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm;
CHD, coronary heart disease; CVD, cardiovascular disease; IHD, ischemic heart disease; MI, myocardial infarction;
TIA, transient ischemic attack; UK-TIA, United Kingdom TIA.
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A post-hoc analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent
Heart Attack Trial (ALLHAT) also aimed to examine the association of visit-to-visit variability of
systolic BP with CVD and mortality outcomes. In their analysis, Muntner et al. defined visit-tovisit variability of systolic BP as the standard deviation across systolic BP measurements from 7
visits that occurred between 6 and 28 months after randomization and the outcomes included were
fatal coronary heart disease or nonfatal myocardial infarction (MI), all-cause mortality, stroke, and
HF. The patients were then followed until they had an occurrence of an outcome event or the end
of the ALLHAT follow-up. During this follow-up period with a mean of 2.7 to 2.9 years and after
multivariable adjustment including mean systolic BP, patients with the most variability in systolic
BP, as indicated by being in the highest versus lowest quintile of standard deviation of systolic BP
(≥14.4 mmHg vs. <6.5 mmHg), had a statistically significant higher risk for fatal coronary heart
disease or nonfatal MI (HR = 1.30; 95% CI: 1.06, 1.61), mortality (HR = 1.58; 95% CI: 0.97,
1.61), stroke (HR = 1.46; 95% CI: 1.06, 2.01), and HF (HR = 1.25; 95% CI: 0.97, 1.61). In
conclusion, this study determined that higher visit-to-visit variability of systolic BP was associated
with an increased risk for CVD and mortality.24
In 2017, Doumas et al. became the first study to specifically analyze patient outcomes
based on time in therapeutic range for systolic BP. They performed a retrospective analysis from
15 Veterans Administration Medical Centers over a 10-year period to determine if consistent
control of TTR for systolic BP was a strong determinant of all-cause mortality among US veterans.
TTR for systolic BP was categorized into 4 quartiles, 0-25%, 26-50%, 51-75%, and 76-100%. The
population for this study consisted of a total of 689,051 Veterans with 54% as hypertensive (3
elevated BPs during the follow-up period), 19.9% as intermediate (MID-hypertension, had 1 or 2
elevated BPs), and 26.1% as normotensive (no elevated BPs). The mortality rates for these
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corresponding 3 groups were 11.5%, 8%, and 1.9%, respectively (p < 0.0001). Among patients
with hypertension, all-cause mortality rates were lowest among patients with high TTR, increasing
gradually from 6.54% in the most controlled group (76-100%), to 8.87%, 15.62%, and 23.52% in
the less controlled groups (51-75%, 26-50%, 0-25%, respectively, p < 0.0001). Cox regression
estimates for survival based on TTR for systolic BP and found that mortality risk with less
consistency in BP control, but the difference between 51-75% and 76-100% were very minimal.
Collectively, these findings suggest that consistency of BP control over time plays a vital role in
all-cause mortality, with TTR >51% to realize long-term survival benefits from BP control.7
In a post hoc analysis of SPRINT, Fatani et al. sought to estimate the independent
association between TTR in systolic BP and major adverse CV events among adults with
hypertension. The TTR was estimated over the first 3 months of follow-up by using linear
interpolation. Fatani et al. categorized TTR for systolic BP into the same 4 quartiles as Doumas et
al., 0-25%, 26-50%, 51-75%, and 76-100%. CV outcomes were then analyzed across TTR groups
over the SPRINT trial time horizon, an average of 3.3 years. Specifically, associations between
TTR and MACE (CVD death, MI, nonmyocardial infarction acute coronary syndrome, stroke, or
acute decompensated HF), individual MACE components, and treatment-related serious adverse
events were analyzed using adjusted Cox proportional hazards regression models. Patients with
TTR for systolic BP of 75-100% were younger and had a lower 10-year CV risk. Additionally,
patients with a greater TTR for systolic BP also had a lower mean systolic BP. For every 1-standard
deviation increase in TTR for systolic BP, there was a significantly decreased risk of first MACE
in the unadjusted model (HR = 0.78; 95% CI: 0.70, 0.77; p < 0.001). In the fully adjusted models,
TTR for systolic BP was significantly associated with first nonfatal MI (HR = 0.75; 95% CI: 0.72,
0.90; p = 0.002) and first HF hospitalization (HR = 0.79; 95% CI: 0.65, 0.97; p = 0.023). However,
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Fatani et al. found no associations between TTR for systolic BP and nonmyocardial infarction
acute coronary syndrome, CVD death, or all-cause death. Overall, TTR for systolic BP was found
to independently predict MACE risk,8 suggesting that TTR monitoring for BP control may be a
useful tool for long-term treatment decision-making.
Section 2.3: Economic Evaluation of Pharmacist Physician Collaborative Care Models
For over a decade, PPCCMs have gained significant traction as a way to implement teambased-care and improve patient outcomes in the primary care setting.25 Within a PPCCM,
pharmacists practice under a collaborative agreement with physicians allowing them to provide
direct patient care for one or more chronic conditions, generally including comprehensive
medication management. For example, pharmacists are often permitted to initiate, titrate, and
discontinue medications as well as order and interpret laboratory tests to help patients manage their
common primary care conditions.26 Although a well-established body of literature has
demonstrated that pharmacists in collaborative primary care settings both effectively improve
patient outcomes for chronic diseases, such as hypertension, and decrease overall healthcare
costs,10–12 economic evaluations of PPCCM are needed to promote implementation of and
reimbursement for these models.
Several past studies have evaluated the cost-effectiveness of PPCCM services for different
chronic disease states in the US.27–31 A study by Hirsch et al. estimated the cost-effectiveness and
cost-benefit of a collaborative endocrinologist-pharmacist Diabetes Intense Medical Management
(DIMM) “Tune Up” clinic for complex diabetes patients versus primary care physician (PCP) care
from 3 separate perspectives: clinic, health system, and payer. They conducted a retrospective
analysis of a cohort of adult patients with type 2 diabetes mellitus and glycosylated hemoglobin
A1c (A1c) 8% who were referred to the DIMM clinic at the Veterans Affairs San Diego Health
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System or were managed by a PCP alone. In general, patients participating in the DIMM clinic
spent more time with clinicians, including medication therapy management, personalized care, and
diabetes education, than those managed by a PCP alone. In base case analyses from the clinic
perspective, DIMM clinics were associated with higher costs but improved patient outcomes.
Specifically, the study authors reported that DIMM clinics, compared to PCP care, cost an
additional $21 per additional percentage point of A1c improvement and $115-164 per additional
patient at target A1c goal level. In contrast, from the health system perspective, DIMM clinicals
were associated with both lower costs and improved patient outcomes. Medical cost avoidance
due to improved A1c associated with each model of care was, on average, $8,793 per DIMM
patient versus $3,506 per PCP patient (p = 0.009). Finally, from the payer perspective, DIMM
group had lower estimated medical costs and greater quality-adjusted life years (QALYs) gained
versus the PCP group over 2-, 5-, and 10-year time frames. For example, at the 5-year time frame,
the DIMM group incurred $2,137,659 medical costs and gained 222 QALYs, while the PCP group
incurred $2,272,572 medical costs and gained 218 QALYs. DIMM was therefore dominant at each
time frame from the payer perspective since it was both more effective and had a lower total cost.27
Overwyk et al. aimed to assess the potential health and budgetary impacts of implementing
a pharmacist-involved team-based hypertension management model in the US. They conducted a
microsimulation model where they evaluated a pharmacist-involved team-based care intervention
among 3 different groups to help estimate CV event incidence and associated healthcare spending
in a cross-section of individuals that were representative of the US population. These 3 groups
included: (1) newly diagnosed hypertension, (2) persistently (1 year) uncontrolled BP, or (3)
treated, yet persistently uncontrolled BP. They reported outcomes over 5 and 20 years and
provided spending thresholds for the intervention to achieve budget neutrality in 5 years from three
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payer perspectives: Medicare, Medicaid, and private payers. The cost of the intervention was
assumed to be $525 per enrollee based on an average of a 1-hour long initial visit and 11 15-minute
visits annually, including three in-person and eight phone visits. Their results showed that a
pharmacist-involved team-based hypertension management model could substantially improve
patient outcomes, preventing 22.9-36.8 million person-years of uncontrolled BP and 77,200230,900 heart attacks and strokes in 5 years. The intervention generated the most favorable health
and economic impact among the groups with persistent uncontrolled BP (i.e., groups 2 and 3).
Assuming an intervention cost $525 per enrollee, the intervention was cost-saving over a five-year
time horizon for Medicare among groups 2 and 3. The intervention was not cost-savings for
Medicaid or private payers but would be budget neutral at an intervention cost of $35 and $180
for Medicaid or private payers, respectively. Overwyk et al. concluded that a physician-pharmacist
collaborative model for hypertension management could significantly improve patient outcomes,
generate cost savings for many Medicare patients, and likely also has acceptable budget impact
for private insurers. 28
Although the studies discussed above depict PPCCM as being less costly compared to usual
care, studies by Polgreen et al. and Kulchaitanaroaj et al. reported PPCCM to be more costly – but
also more effective - than usual care for hypertension management.29–31 Polgreen et al. conducted
a cost-effectiveness analysis of physician-pharmacist collaborations to improve hypertension
control from the societal perspective with data from the Collaboration Among Pharmacist and
Physicians to Improve Blood Pressure Now (CAPTION) trial. Costs were assigned to medications
as well as pharmacist and physician time, and cost-effectiveness ratios were calculated based on
changes in BP and hypertension control rates. Specifically, provider costs were generated by
multiplying patient-specific pharmacist or provider time by the average compensation rates for
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pharmacists ($56.01/hr) or physicians ($88.43/hr). Patients spent 15 to 1,044 minutes with the
pharmacist, with an average of 155 minutes, and they had more visits compared to that of the
physician group.29 After 9 months, patients in the pharmacist group had lower average systolic
(6.1 mmHg) and diastolic BP (2.9 mmHg) and were more likely to be controlled (43% vs. 34%)
than patients managed by physicians alone.. Total costs, which were the sum of drug costs,
physician time, and pharmacist costs, were higher among the collaboratively managed patients
($1,462.87 vs. $1,259.94). Polgreen et al. reported three cost-effectiveness ratios: the incremental
cost to lower systolic ($33.27) and diastolic BP by 1 mmHg ($69.98) and the cost to increase the
population-level rate of BP control by 1 percentage point ($22.55).The findings from Polgreen et
al. showed that although pharmacists spent a substantially longer time with patients during visits,
the additional pharmacist care resulted in statistically and clinically significant reductions in BP
compared to physicians alone that were highly cost-effective.29
Kulchaitanaroaj et al. performed two separate economic studies to determine the economic
impact of PPCCM. The first study, published in2012, compared the costs associated with usual
physician-based care vs. a physician-pharmacist collaborative intervention for the management of
hypertension. The cost calculation, which included costs of provider time, laboratory tests, and
antihypertensive medications for a six-month period, was determined by using healthcare
utilization and outcomes from prospective, cluster randomized controlled clinical trials. Like the
study by Polgreen et al., provider costs were generated by using the average compensation rate of
the physician ($77.64 per hour for family and general practitioners, $79.33 per hour for other
physicians and surgeons, and $50.14 per hour for pharmacists). However, this 2012 study by
Kulchaitanaroaj et al. also included the time physician and pharmacists collaborated into the total
costs. Although physicians spent similar among of time on direct-patient care in both groups, the
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total time spent by primary care physicians in the intervention group was higher than the control
group due to the added time spent on collaboration with pharmacist. This resulted in higher
adjusted total costs in the collaborative intervention group ($774.90) than the control group
($445.75; difference: $329.16, p <0.001).The results of the cost-effectiveness analysis suggested
that the incremental cost of pharmacist-physician collaborative care, over physician care alone,
was $1,338.05 for each additional patient who attains BP control over a 6-month time horizon.30
The second study by Kulchaitanaroaj et al., published in 2017 and it was a cost-utility
analysis that estimated long-term costs and outcomes of a physician-pharmacist collaborative
intervention compared with physician management along for treating essential hypertension. This
study utilized a Markov model cohort simulation with a 6-month cycle to predict acute coronary
syndrome, stroke, and HF throughout a patient’s lifetime. Direct medical costs were based on the
payer perspective; treatment costs of the physician-pharmacist intervention included time primary
care physicians and pharmacists spent providing direct patient care and collaborating, specialist
time for direct patient care during acute care visits, laboratory tests, antihypertensive medications,
and overheads. In their base case analysis, they found that the average discounted costs of
hypertension treatment and vascular diseases in the physician-pharmacist collaborative
intervention were greater than the costs of usual care by $3,817.54 per person over a lifetime
horizon. The intervention increased QALYs by 0.14 per person compared with that of usual care,
resulting in a lifetime incremental cost for collaborative pharmacist-physician management of
hypertension of $26,807.83 per QALY gained.31 Compared to the other studies mentioned above,
Polgreen et al. and Kulchaitanaroaj et al. found PPCCM to be more costly due to their utilization
of time-based costing and pharmacists spend more time with their patients compared to usual
care.29–31 Nonetheless, the three studies reported incremental cost-effectiveness and cost-utility
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ratios generally recognized to indicate that PPCCMs are cost-effective in the management of
hypertension.
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CHAPTER 3: SPECIFIC AIM 1
Specific Aim 1:
To assess the cost-benefit and cost-effectiveness of PPCCM relative to usual care in patients with
hypertension with a TTR for systolic BP-based decision analysis model.
Section 3.1: Methods
Model Overview:
For specific aim 1, we used a decision analysis model (Figure 1) to evaluate the costeffectiveness of two hypertension management practices, PPCCM and usual care. The PPCCM
model was based on that reported by Dixon et al., consisting of an urban safety-net free clinic in
Richmond, Virginia that primarily serves uninsured patients. In this model, volunteer physicians
and nurse practitioners establish diagnoses and provide yearly wellness visits while pharmacists
manage all aspects of drug therapy to achieve therapeutic goals for chronic diseases such as
hypertension, diabetes, and heart failure.13 The population studied in this analysis consisted of
adult patients who were previously diagnosed with hypertension (defined as office-based BP 
140/90 mmHg) or were receiving antihypertensive medication(s).13 A three-year time horizon was
chosen, reflecting the time frame of available data linking TTR for systolic BP (0-25%, 26-50%,
51-75%, and 76-100%) to CV outcome measures (nonfatal MI, stroke, HF, and CVD death).8,9
The time horizon is consistent with the follow-up duration from the SPRINT trial, which was
terminated early given the clinical benefit of intensive BP control within three years of
treatment.9,32 Further, the time horizon aligns with the shorter time frame utilized in costeffectiveness models from the payer perspective.33 The decision analysis model was developed in
TreeAge Pro (TreeAge Software Inc, Williamstown MA). Institutional Review Board approval
was not required as this research did not qualify as human subjects research.
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Figure 1: Decision Tree Analysis for the Cost-Benefit of PPCCM Compared with Standard
Usual Care on Time in Target Range for Systolic Blood Pressure in Hypertension
Management
No CV Event
Nonfatal MI
0-25%

Stroke

26-50%

HF

51-75%

CVD Death

PPCCM

76-100%

No CV Event

Hypertension
Management

Nonfatal MI

0-25%

Stroke

26-50%

HF

51-75%

CVD Death

Usual
Care

76-100%
Abbreviations Used: PPCCM, pharmacist-physician collaborative care model; CV, cardiovascular; CVD,
cardiovascular disease; MI, myocardial infarction; HF, heart failure
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Effectiveness: Time in Target Systolic Blood Pressure Range and CV Event Outcomes
Base case parameters for the decision analysis model are listed in Table 3. The probabilities
that patients managed with PPCCM and usual care would achieve levels of BP control within each
of the 4 TTR for systolic BP quartiles were based on previously published data.13 Although the
published data on the effectiveness of PPCCM had a one-year study duration,13 subjects in the
model were assumed to stay in the same quartile of target BP range over the 3-year time horizon
to facilitate linking the PPCCM effectiveness data to the clinical data on the association between
TTR for systolic BP and CV events. Four CV events (nonfatal MI, stroke, HF, and CVD death)
were selected for model inclusion based on available probabilities and hazard ratios from published
data on CV outcomes associated with TTR for systolic BP quartiles.8,9 Specifically, data on TTR
for systolic BP quartiles and CV outcomes were derived from a post-hoc analysis of the SPRINT
trial, a randomized, controlled, open-label trial of intensive versus standard BP control.9 Patients
within the SPRINT trial were censored after their first CV event, precluding analysis of subsequent
events. Accordingly, CV events in this study were assumed to be mutually exclusive. Patients who
did not incur one of these four events were assumed to have had no major CV event.
Hypertension Management and CV Event Costs
The decision analysis model incorporated direct medical costs, including both
programmatic costs (i.e., direct costs for provider time) and downstream healthcare utilization
associated with CV events (Table 3). Cost data were obtained from publicly available data and
recently published cost-effectiveness analysis.32,34,35 Provider visit utilization data were obtained
from a real world analysis of PPCCM vs. usual care for the management of hypertension. 13
Specifically, for the cost of the PPCCM program, patients were assumed to have been seen for
hypertension management six times per year by a pharmacist13 and once per year by a physician.
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Subjects in the usual care group were assumed to be seen three times per year by a physician. 13
The cost per pharmacist visit reflected the Current Procedural Terminology (CPT) code 99211
(level 1), an “incident-to” billing code used by pharmacists given a lack of provider status and
eligibility to bill at a higher level.
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For usual care visits, the CPT code 99213 was used for

evaluation and management/outpatient visits.35 One-time costs of treating each CV event were
obtained from the cost-effectiveness analysis of the SPRINT trial.32 Costs of hypertensive
medications were assumed to be the same for both PPCCM and usual care given a lack of
comparative medication use data and hence excluded from the model. Additionally, since the most
commonly utilized hypertensive medications are generic and typically inexpensive, 36 they were
unlikely to have a major impact on costs of care. All costs were inflated to 2020 United States
Dollar (USD) using the medical care component of the Consumer Price Index.
Table 3: Effectiveness and Cost Inputs for Decision Analysis Model
Basecase
Range
Reference
value
Probability of TTR for Systolic BP by Hypertension Management Approach
Variables

PPCCM
0.170-0.260
0.290-0.430
0.240-0.370
0.098-0.150

Dixon et al, 202013
Dixon et al, 202013
Dixon et al, 202013
Dixon et al, 202013

0-25%
0.550
0.400-0.600
26-50%
0.340
0.270-0.400
51-75%
0.050
0.042-0.064
76-100%
0.060
0.044-0.066
Probability of CV Events by TTR for Systolic BP
Outcome event rates of patients in TTR for Systolic BP
0-25%
0.035
0.027-0.045
Nonfatal MI
0.020
0.014-0.028
Stroke
0.022
0.016-0.031
Heart Failure
0.017
0.012-0.024
CVD death
0.906
No CV event
Hazard ratio of patients in TTR for Systolic BP 26-50%
Nonfatal MI
0.83
0.57-1.18
Stroke
0.83
0.55 -1.27
Heart Failure
1.30
0.94-2.01
CVD death
0.69
0.42-1.15

Dixon et al, 202013
Dixon et al, 202013
Dixon et al, 202013
Dixon et al, 202013

0-25%
26-50%
51-75%
76-100%

0.210
0.360
0.310
0.120

Usual Care

Wright et al, 20159
Wright et al, 20159
Wright et al, 20159
Wright et al, 20159
Calculation
Fatani et al, 20218
Fatani et al, 20218
Fatani et al, 20218
Fatani et al, 20218
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No CV event
1.03
Calculation
Hazard ratio of patients in TTR for Systolic BP 51-75%
Nonfatal MI
0.87
0.61-1.24
Fatani et al, 20218
Stroke
0.58
0.36 -0.93
Fatani et al, 20218
Heart Failure
0.84
0.54-1.29
Fatani et al, 20218
CVD death
0.53
0.30-0.92
Fatani et al, 20218
No CV event
1.12
Calculation
Hazard ratio of patients in TTR for Systolic BP 76-100%
Nonfatal MI
0.69
0.46-1.04
Fatani et al, 20218
Stroke
0.40
0.22-0.73
Fatani et al, 20218
Heart Failure
0.59
0.34-1.02
Fatani et al, 20218
CVD death
0.45
0.23-0.86
Fatani et al, 20218
No CV event
1.25
Calculation
Programmatic Costs
Annual PPCCM Pharmacist Visits, No.
6
4-12
Dixon et al, 202013
PPCCM cost per visit
$24
$19-$29
ASHP, 201934
Annual Physician Visits, No.
PPCCM Group
1
1-2
Assumption
Usual Care Visits
3
1-6
Dixon et al, 202013
Physician cost per visit
$90
$72-$108
CMS, 201935
Total cost of PPCCM
$702
$562-$842
ASHP, 201934
Total cost of usual care
$810
$648-$972
CMS, 201935
Downstream Healthcare Costs
One-time cost of nonfatal MI
$24,089
$15,372-$32,306
Bress et al, 201732
One-time cost of stroke
$15,678
$6,001-$42,039
Bress et al, 201732
One-time cost of heart failure
$11,678
$11,669-$16,580
Bress et al, 201732
One-time cost of CVD death
$19,514
$12,560-$33,024
Bress et al, 201732
Abbreviations Used: ASHP, American Society for Health Systems Pharmacists; CMS, Centers for Medicare and
Medicaid Services; CV, cardiovascular; CVD, cardiovascular disease; MI, myocardial infarction; PPCCM,
pharmacist-physician collaborative care model; TTR, time in target range; BP, blood pressure

Sensitivity Analyses
One-way deterministic sensitivity analyses were performed on all model variables to
account for uncertainty in the parameter estimates for the two hypertensive management options.
Additionally, threshold analyses were performed varying the cost per pharmacist visit, the number
of annual pharmacist visits among patients in the PPCCM program, and the number of annual
physician visits among patients in usual care to assess the values at which the programmatic costs
of the two models would be equal.
Section 3.2: Results
In base case analyses, PPCCM hypertension management was associated with lower total
program costs (difference: $-108.00) and lower downstream medical expenditures (difference: -
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$162.86) when compared to usual care (Table 4). For every 10,000 hypertension patients managed
with PPCCM vs. usual care over a three-year time horizon, approximately 27 CVD deaths, 29
strokes, 21 non-fatal MIs, and 12 incident HF diagnoses are expected to be averted.
PPCCM was associated with lower downstream medical expenditures across all parameter
ranges tested in the deterministic sensitivity analysis. The expected downstream healthcare savings
were most sensitive to the likelihood that patients receiving usual care spend little to no TTR for
systolic BP (0-25%) (Figure 2). PPCCM was expected to reduce healthcare expenditures even as
the proportion of usual care patients with TTR for systolic BP 0-25% was varied from its base case
value of 55%, the probability observed by Dixon et al.,13 to the lowest probability tested, 40%.
The program costs of hypertension management with PPCCM, while lower than those of
usual care in base case analyses, were sensitive to the number of visits with a physician (usual care
patients) and pharmacist (PPCCM patients) (Figure 3). Due to the substantial difference in CPT
code reimbursement for pharmacist vs. usual care visits, a patient in the PPCCM program that was
seen six times per year by a pharmacist and once per year by a physician was still cheaper than a
patient in the usual care group that was seen three times per year by a physician. However, in oneway sensitivity analysis, the cost of PPCCM hypertension management exceeded the cost of usual
care when independently varying the number of both types of provider visits. First, if the number
of hypertension-related physician visits each year was reduced from three to one while holding the
number of PPCCM-related visits constant, the cost of the PPCCM hypertension management
exceeded the cost of usual care by $432 over the 3-year study period. Second, when the number
of pharmacist visits among patients enrolled in PPCCM increased from six per year to twelve while
the number of physician visits in the usual care group (n = 3) was held constant, PPCCM was
associated with an incremental program cost of $324 over usual care.
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In threshold analysis, the costs of the PPCCM and usual care programs became equal when
the unit cost of pharmacist visits increases 62.5% to $39. The program costs were also equal when
the number of PPCCM patient visits increased from six to 10 pharmacist visits per year or the
number of usual care patient visits decreased from three to two physician visits per year.
Table 4: Cost-Effectiveness Results for Decision Analysis Model
PPCCM

Usual care

Difference

Cardiovascular Events
Nonfatal MI
0.0300
0.0321
21 per 10,000
Stroke
0.0149
0.0178
29 per 10,000
Heart failure
0.0225
0.0237
12 per 10,000
CVD death
0.0116
0.0143
27 per 10,000
Total downstream healthcare expenditures
$1,535.82
$1,698.64
- $162.82
Total program costs
$702.00
$810.00
- $108.00
Cost-benefit ratio
Dominant
Abbreviations Used: PPCCM, pharmacist-physician collaborative care model; MI, myocardial infarction; CVD,
cardiovascular disease

Figure 2: Tornado Diagram of Incremental Downstream Healthcare Expenditures among
Patients Receiving PPCCM vs. Usual Care for Decision Analysis Model
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Figure 3: Tornado Diagram of Incremental Cost of PPCCM vs. Usual Care for Decision
Analysis Model
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CHAPTER 4: SPECIFIC AIM 2
Specific Aim 2:
2a. To assess the cost-benefit and cost-effectiveness of PPCCM relative to usual care in patients
with hypertension with a TTR for systolic BP-based Markov model.
2b. To compare the cost-benefit and cost-effectiveness of PPCCM relative to usual care in patients
with hypertension as assessed by the decision analysis and Markov models.
Section 4.1: Methods
Model Overview:
For specific aim 2, we used a Markov model (Figure 4) to evaluate the cost-effectiveness
of two hypertension management practices, PPCCM and usual care. The population studied in this
analysis consisted of adult patients who were previously diagnosed with hypertension (defined as
office-based BP  140/90 mmHg) or were receiving antihypertensive medication(s).13 A threeyear time horizon was chosen, reflecting the time frame of available data linking TTR for systolic
BP (0-25%, 26-50%, 51-75%, and 76-100%) to CV outcome measures (nonfatal MI, stroke, HF,
and CVD death).8,9 The time horizon is consistent with the follow-up duration from the SPRINT
trial, which was terminated early given the clinical benefit of intensive BP control within three
years of treatment.9,32 Like the decision analysis model, the time horizon aligns with the shorter
time frame utilized in cost-effectiveness models from the payer perspective.33
The primary differences between the decision analysis model and the Markov model are
that the Markov model incorporates (1) the probability of the recurrence of an initial CV event,
(2) probability of death after a specific CV event over the three-year time horizon,37 and (3) the
inclusion of incremental costs in patients with a past event beyond the initial cost of an event.
Specific methodological differences are highlighted in Table 5. The Markov model was developed
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in TreeAge Pro (TreeAge Software Inc, Williamstown MA). Institutional Review Board approval
was not required as this research did not qualify as human subjects research.
Table 5: Methodological Differences between Decision Analysis Model and Markov Model
Methodological Attribute

Decision Analysis Model

Markov Model
Included for recurrences of the
Recurrent CV Events
Not included
same type of CV event
Included as a CV event among both
Included as a CV event among
those who did not have the other
patients who did not have the other
CVD Death
included CV events (e.g., MI,
included CV events (e.g., MI,
stroke) and those who had an initial
stroke)
non-fatal event but later died
One-time costs of treating a CV
One-time costs of treating the one
Cost of Events
event plus incremental future costs
CV event
among patients with a past event
Abbreviations Used: CV, cardiovascular; CVD, cardiovascular disease; MI, myocardial infarction
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Figure 4: Markov Model for the Cost-Benefit of PPCCM Compared with Standard Usual
Care on Time in Target Range for Systolic Blood Pressure in Hypertension Management

Hypertension
Management

Usual
Care

PPCCM

TTR for
Systolic
BP

Post
Nonfatal
MI

Post
Stroke

No CV
Event

Nonfatal
MI

Stroke

HF

Post HF

Post
Nonfatal
MI

Post
Stroke

Post HF

CVD
Death

CVD
Death

Abbreviations Used: PPCCM, pharmacist-physician collaborative care model; CV, cardiovascular; CVD,
cardiovascular disease; MI, myocardial infarction; HF, heart failure
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Effectiveness: Time in Target Systolic Blood Pressure Range and CV Event Outcomes
Base case parameters for the Markov model are listed in Table 6. The probabilities that
patients managed with PPCCM and usual care would achieve levels of BP control within each of
the 4 TTR for systolic BP quartiles were based on previously published data.13 Although the
published data on the effectiveness of PPCCM had a one-year study duration,13 subjects in the
model were assumed to stay in the same quartile of target BP range over the 3-year time horizon
to facilitate linking the PPCCM effectiveness data to the clinical data on the association between
TTR for systolic BP and CV events. Four CV events (nonfatal MI, stroke, HF, and CVD death)
were selected for model inclusion based on available probabilities and hazard ratios from published
data on CV outcomes associated with TTR for systolic BP quartiles.8,9 Specifically, data on TTR
for systolic BP quartiles and CV outcomes were derived from a post-hoc analysis of the SPRINT
trial, a randomized, controlled, open-label trial of intensive versus standard BP control.9
Unlike the decision analysis model where patients were censored after their first CV event
precluding analysis of subsequent events, we incorporated the probability of recurring CV events
and death following an initial CV event in the Markov model. We utilized published data to
determine the probability of the recurrence of the same CV event that the patient first had and the
probability of death after their specific CV event.37
Hypertension Management and CV Event Costs
The Markov model incorporated direct medical costs, including both programmatic costs
(i.e., direct costs for provider time) and downstream healthcare utilization associated with CV
events (Table 6). Refer to Specific Aim 1 for a detailed explanation of the programmatic costs
included. Cost data were obtained from publicly available data and recently published costeffectiveness analysis.32,34,35,37 Like the decision analysis model, one-time costs of treating each
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CV event were obtained from the cost-effectiveness analysis of the SPRINT trial32 and costs of
hypertensive medications were assumed to be the same for both PPCCM and usual care. The core
difference between the decision analysis model and the Markov model is that in the Markov model,
we included long-term incremental costs of treating each CV event from a previously published
cost-effectiveness analysis.37 These long-term incremental costs included all inpatient and
outpatient costs during the 3-month period following a CV event.37 All costs were inflated to 2020
USD using the medical care component of the Consumer Price Index.
Table 6: Effectiveness and Cost Inputs for Markov Model
Basecase
Range
Reference
value
Probability of TTR for Systolic BP by Hypertension Management Approach
Variables

PPCCM
0.170-0.260
0.290-0.430
0.240-0.370
0.098-0.150

Dixon et al, 202013
Dixon et al, 202013
Dixon et al, 202013
Dixon et al, 202013

0-25%
0.550
0.400-0.600
26-50%
0.340
0.270-0.400
51-75%
0.050
0.042-0.064
76-100%
0.060
0.044-0.066
Probability of CV Events by TTR for Systolic BP
Outcome event rates of patients in TTR for Systolic BP
0-25%
0.035
0.027-0.045
Nonfatal MI
0.020
0.014-0.028
Stroke
0.022
0.016-0.031
Heart Failure
0.017
0.012-0.024
CVD death
0.906
No CV event
Hazard ratio of patients in TTR for Systolic BP 26-50%
Nonfatal MI
0.83
0.57-1.18
Stroke
0.83
0.55 -1.27
Heart Failure
1.30
0.94-2.01
CVD death
0.69
0.42-1.15
No CV event
1.03
Hazard ratio of patients in TTR for Systolic BP 51-75%
Nonfatal MI
0.87
0.61-1.24
Stroke
0.58
0.36 -0.93
Heart Failure
0.84
0.54-1.29
CVD death
0.53
0.30-0.92
No CV event
1.12
Hazard ratio of patients in TTR for Systolic BP 76-100%
Nonfatal MI
0.69
0.46-1.04

Dixon et al, 202013
Dixon et al, 202013
Dixon et al, 202013
Dixon et al, 202013

0-25%
26-50%
51-75%
76-100%

0.210
0.360
0.310
0.120

Usual Care

Wright et al, 20159
Wright et al, 20159
Wright et al, 20159
Wright et al, 20159
Calculation
Fatani et al, 20218
Fatani et al, 20218
Fatani et al, 20218
Fatani et al, 20218
Calculation
Fatani et al, 20218
Fatani et al, 20218
Fatani et al, 20218
Fatani et al, 20218
Calculation
Fatani et al, 20218

39

Stroke
0.40
0.22-0.73
Heart Failure
0.59
0.34-1.02
CVD death
0.45
0.23-0.86
No CV event
1.25
Probability of Recurring CV Events

Fatani et al, 20218
Fatani et al, 20218
Fatani et al, 20218
Calculation

Events, probability of (per month)
Nonfatal MI 0.000598 0.00048-0.00072 Richman et al, 201637
Stroke 0.000260 0.00021-0.00031 Richman et al, 201637
Heart Failure 0.000449 0.00036-0.00054 Richman et al, 201637
Death after MI 0.008355 0.00668-0.01003 Richman et al, 201637
Death after Stroke 0.022691 0.01815-0.02723 Richman et al, 201637
Death after Heart Failure 0.009084 0.00727-0.01090 Richman et al, 201637
Programmatic Costs
Annual PPCCM Pharmacist Visits, No.
6
4-12
Dixon et al, 202013
PPCCM cost per visit
$24
$19-$29
ASHP, 201934
Annual Physician Visits, No.
PPCCM Group
1
1-2
Assumption
Usual Care Visits
3
1-6
Dixon et al, 202013
Physician cost per visit
$90
$72-$108
CMS, 201935
Total cost of PPCCM
$702
$562-$842
ASHP, 201934
Total cost of usual care
$810
$648-$972
CMS, 201935
Downstream Healthcare Costs
One-time cost of nonfatal MI
$24,089 $15,372-$32,306
Bress et al, 201732
One-time cost of stroke
$15,678
$6,001-$42,039
Bress et al, 201732
One-time cost of heart failure
$11,678 $11,669-$16,580
Bress et al, 201732
One-time cost of CVD death
$19,514 $12,560-$33,024
Bress et al, 201732
Long-term incremental cost of nonfatal MI
$685
$548-$822
Richman et al, 201637
Long-term incremental cost of stroke
$408
$326-$490
Richman et al, 201637
Long-term incremental cost of heart failure
$754
$603-$905
Richman et al, 201637
Abbreviations Used: ASHP, American Society for Health Systems Pharmacists; CMS, Centers for Medicare and
Medicaid Services; CV, cardiovascular; CVD, cardiovascular disease; MI, myocardial infarction; PPCCM,
pharmacist-physician collaborative care model; TTR, time in target range; BP, blood pressure

Sensitivity Analyses
One-way deterministic sensitivity analyses were performed on all model variables to
account for uncertainty in the parameter estimates for the two hypertensive management options.
Section 4.2: Results
In base case analyses, PPCCM hypertension management was associated with lower
downstream medical expenditures (difference: -$173.05) when compared to usual care (Table 6).
Like the decision analysis model, PPCCM hypertension management was associated with lower
total program costs (difference: $-108.00) since we utilized the same time horizon and number of
patients visits. For every 10,000 hypertension patients managed with PPCCM vs. usual care over
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a three-year time horizon, approximately 16 CVD deaths, 51 strokes, 42 non-fatal MIs, and 48
incident HF diagnoses are expected to be averted.
PPCCM was associated with lower downstream medical expenditures across all parameter
ranges tested in the deterministic sensitivity analysis. The expected downstream healthcare savings
were most sensitive to the probability of MI in TTR for systolic BP 0-25%. (Figure 5).
Table 7: Cost-Effectiveness Results of Markov Model
PPCCM

Usual care

Difference

Cardiovascular Events
Nonfatal MI
0.0707
0.0749
42 per 10,000
Stroke
0.0273
0.0324
51 per 10,000
Heart failure
0.0494
0.0542
48 per 10,000
CVD death
0.0388
0.0404
16 per 10,000
Total downstream healthcare expenditures
$2,084.85
$2,257.90
- $173.05
Total program costs
$702.00
$810.00
- $108.00
Cost-benefit ratio
Dominant
Abbreviations Used: PPCCM, pharmacist-physician collaborative care model; MI, myocardial infarction; CVD,
cardiovascular disease
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Figure 5: Tornado Diagram of Incremental Downstream Healthcare Expenditures among
Patients Receiving PPCCM vs. Usual Care for Markov Model
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CHAPTER 5: DISCUSSION
Section 5.1: Main Findings
This study quantifies the cost-effectiveness of PPCCM for hypertension management to
improve BP control and CV outcomes. Previous studies evaluated the impact of PPCCM on TTR
for systolic BP13 and the association between TTR for systolic BP and CV outcomes,8 but no
pharmacoeconomic analysis had combined these findings to model the cost-effectiveness of
PPCCM from the payer perspective.
Both the decision analysis model and Markov model found that patients enrolled in the
PPCCM incurred fewer costs associated with their direct hypertension management. The lower
PPCCM program costs reflect the significantly lower cost of pharmacist time as billed by “incident
to” CPT codes than physician visits for hypertension. In threshold analysis for the decision analysis
model, the direct cost of provider time was lower for usual care if patients receiving usual care had
fewer than two physician visits per year. However, previous studies suggests that approximately
80% of adult patients with hypertension have two or more hypertension-focused physician visits
per year.38 Nonetheless, given that the cost of PPCCM hypertension management exceeded the
cost of usual care among patients with only one hypertension-related physician visit each year,
payers concerned with the immediate budget impact of PPCCM reimbursement may focus on
coverage for patients with at least two or three hypertension-related physician visits annually, as
PPCCM is cost-neutral and cost-savings, respectively, in these populations. A second threshold
analysis for the decision analysis model found that the direct program cost of PPCCM would equal
that of usual care if patients met 10 times with a pharmacist annually. This well exceeds the number
of previously observed pharmacist appointments for patients in two different PPCCM
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programs,13,29 suggesting that the PPCCM model is likely to save upfront hypertension
management costs from the payer perspective.
While this study found that the direct intervention costs of the PPCCM were lower than
that of usual care in both models, several past cost-effectiveness analyses on pharmacist-physician
collaborative care for the management of hypertension found increased costs for patients in
PPCCM.29,31 A previous cost-effectiveness analysis from a societal perspective on a physician–
pharmacist collaboration to improve hypertension control conducted by Polgreen et al. reported
that provider costs over a 9-month period were $238.96 for PPCCM patients and $113.67 for usual
care patients managed only by a physician.29 Rather than using CPT billing codes, that study
determined costs based on time spent with pharmacists and providers and their average
compensation rates, likely due to its societal, rather than payer, perspective. Thus, while usual care
patients had the same number of physician visits (median: three visits) as was assumed for our
analyses, the cost of those three visits was calculated to be only $113.67. Kulchaitanaroaj et al.
similarly reported higher costs for PPCCM in two analyses,30,31 but, like Polgreen,29 used timebased costing, resulting in higher provider costs among PPCCM patients ($345.25) than those in
usual care ($111.84).30 The use of CPT codes in this analysis generated higher expected costs for
physician visits but more accurately reflects hypertension management costs from the payer
perspective.
Current Procedural Terminology “incident-to” billing, in which the physician bills,
receives payment, and reimburses the pharmacist, offers payers an opportunity to implement
payment for services within existing frameworks of physician reimbursement. The use of incidentto billing and CPAs may also reduce barriers to PPCCM implementation from the pharmacy
perspective, as a lack of clear reimbursement was cited by study authors as a potential barrier to
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more widespread PPCCM dissemination. Physician champions for the model can help to facilitate
reimbursement efforts and streamline referrals, as the pharmacists practicing under the CPAs in
the collaborative care model routinely reported encountering new complaints from patients.
When compared to usual care, PPCCM was associated with lower downstream healthcare
expenditures, saving an expected $162.82 over a three-year time horizon in our decision analysis
model. Within our Markov model, PPCCM was associated with lower downstream healthcare
expenditures, saving an expected $173.05 over a three-year time horizon.

Our finding of

downstream healthcare savings is consistent with the majority of economic evaluations of clinical
pharmacy services for chronic disease state management that incorporate long-term healthcare
expenditures.39 Pharmacist-delivered medication management and hypertension education have
consistently been shown to reduce BP,40 which, in turn, is associated with CV events. Further, the
more frequent pharmacist interactions in the PPCCM model may have facilitated the development
of a stronger patient-pharmacist relationship and higher levels of trust, thereby enabling patients
to better manage their chronic diseases.41
Our goal in conducting a decision analysis model and a Markov model was to determine if
the decision analysis model substantially underestimated the value of pharmacist services due to
its simplicity. Overall, both models resulted in similar expected cost savings per patient over a
three-year time horizon ($162.82 for the decision analysis model vs. $173.05 for the Markov). The
Markov model results did predict that PPCCM would be associated with more prevented CV
events. However, given that there were few CV events over the short, 3-year time horizon, the
Markov model did not result in substantially more cost savings attributed to PPCCM. Therefore,
for short time horizons within the hypertension disease state, we do not expect that the use of the
decision analysis model would substantially underestimate cost savings attributed to pharmacists.
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For longer time horizons, where repeat CV events may come more into play, a Markov model will
be able to capture more of the pharmacists’ value for patient health outcomes and downstream
healthcare costs.
While QALYs were not utilized as an outcome in this study, past cost-utility analyses of
pharmacist-led or collaborative hypertension management have reported such programs to be costeffective. Bryant et al. modeled 10-year health outcomes and one-year healthcare costs associated
with pharmacist-led hypertension care in Black-owned barbershops in the Los Angeles Barbershop
Blood Pressure Study from a healthcare sector perspective.14 They reported a mean cost of $42,717
per QALY gained. Kulchaitanaroaj et al. similarly reported a PPCCM to be highly cost effective
from the payer perspective ($26,807 per QALY gained). This study thus adds to a growing body
of literature suggesting that pharmacist collaboration in the management of chronic conditions not
only benefits the health outcomes of the patient but does so in a cost-effective manner.42–44 PPCCM
may have other benefits not captured in economic evaluations, including decreased physician
workload and an ability to reach underserved populations.25 There is a significant health
professional shortage in rural areas and people living in these areas rely heavily on pharmacists
for their healthcare needs. Therefore, pharmacists are in a unique position to fill the shortage gap
and reach these underserved populations.
Section 5.2: Limitations
This research included several limitations. The TTR for systolic BP data was collected
from a study with a small population of 112 patients (56 patients in both PPCCM and usual care),
which may limit generalizability,13 though the impact of the PPCCM model on hypertension
management reported by Dixon et al.13 was similar to that reported elsewhere.17,18
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This study did not incorporate the cost of medications due to the lack of information on
medication utilization among patients in the two groups. The post hoc analysis of SPRINT data by
Fatani et al. indicated the number of BP-lowering agents based on the participants TTR for systolic
BP,8 but it is not known whether pharmacist involvement to promote higher TTR for systolic BP
would systematically change the number of BP-lowering agents required to improve BP control.
While Dixon et al. did not report specific medication utilization in the PPCCM and usual care
groups,13 the antihypertensives used by both PPCCM and usual care patients were predominately
low-cost generics, minimizing the effect of drug costs on the cost-effectiveness of the program.
Additionally, indirect costs were not included in our analysis due to a lack of data linking TTR
for systolic BP to changes in productivity, absenteeism, and other indirect costs; similarly, utility
values have not yet been established by TTR for systolic BP ranges However, given that numerous
adverse CV outcomes have been associated with indirect costs of lost productivity due to morbidity
and mortality,45 it is likely that the lack of indirect costs in this study resulted in an underestimation
of the downstream savings associated with PPCCM. Future research is needed to assess indirect
costs and potential changes in QALYs associated with improvements in TTR for systolic BP.
Furthermore, costs for payer oversight, including quality assurance (QA)/auditing of the benefit
were not considered; substantial QA costs may reduce the reported savings associated with
PPCCM implementation.
This study evaluated the impact of hypertension management with PPCCM on CV
outcomes and associated costs over a three-year time frame. Hypertension is a chronic disease and
is linked to health consequences including multiple MIs, strokes, HF exacerbations. The data we
utilized for the Markov model only included the probability of recurrence of the same CV event.37
However, a patient can experience different CV events over their lifetime. For example, a patient
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can initially have a nonfatal MI and then later on in life experience a stroke or get diagnosed with
HF. Therefore, our study may have underestimated the impact of PPCCM on long-term adverse
CV events associated with TTR for systolic BP in hypertension management.
Finally, this study used effectiveness estimates from a real-world study on PPCCM for
hypertension management.13 However, a recent nationwide survey found that only about half of
patients considered themselves likely to participate in clinical pharmacy services under a CPA,
despite their perceptions that such services improve physician-pharmacist coordination.46 If
eligible patients choose not to participate in PPCCM services where available, the scope of
downstream benefits realized by widespread programmatic access would be more limited than
with widespread adoption.
Section 5.3: Future Directions
This research reports the cost-benefit of PPCCM versus usual care on TTR for systolic BP
for four CV outcomes. The data for TTR for systolic BP and CV outcomes was from previously
published data. The direct effect of PPCCM and usual care as it relates to patient outcomes and
costs has not been reported. The first aim of our study with the decision analysis model was
designed to evaluate only the first occurrence of CV event or death. Although for our second aim
we conducted a Markov model, we were only able to find the probability of recurrence of the same
CV event within published literature. Additionally, both the decision analysis model and Markov
model only had a three-year time horizon to align with the payer perspective. Therefore, future
research that includes a Markov model investigating different subsequent CV events over a
patient’s lifetime should be conducted. Also, the cost-benefit of PPCCM with the addition of
hypertensive medication costs should also be explored. Different CV outcomes can result in
additional hypertensive medications, which can impact the costs from the payer perspective. Since
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TTR for systolic BP is a novel measure of BP control, there has not been any published literature
that links TTR for systolic BP with health-related utilities. If TTR for systolic BP becomes widely
accepted and studied, we can then incorporate its health-related utilities into both the decision
analysis model and Markov model to better understand its impact on a patient’s quality of life.
Section 5.4: Conclusion
In summary, this was the first study to evaluate the cost-effectiveness and cost-benefit of
PPCCM and usual care on TTR for systolic BP in patients with hypertension. Even though the
Markov model included recurrent CV events, the cost savings attributed to PPCCM over a threeyear time horizon were similar between the decision analysis model and Markov model. Therefore,
our findings suggest that the decision analysis model did not meaningfully underestimate the value
of pharmacist services despite its simplicity relative to the Markov model. Overall, PPCCM was
less costly to administer and resulted in reduced downstream adverse CV events as well as
healthcare savings relative to usual care. Although further research is needed to evaluate the longterm costs and outcomes of PPCCM, payer coverage of PPCCM services may prevent future
healthcare costs and improve patient CV outcomes.
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